Serum Institute will also produce Russian vaccine Sputnik-V, DCGI approves

- Indigenous vaccine manufacturers, including serum, demanded government protection

New delhi date. Saturday, June 5, 2021

Vaccine production in the country is in full swing to curb the Koro epidemic. In the meantime, the Serum Institute of India had sought approval from the Drug Controller General of India (DCGI) for a test license to manufacture the Russian vaccine Sputnik-V in India. The DCGI on Friday approved the serum for production of Sputnik-V.

Serum will be able to manufacture Sputnik-V in India after getting DCGI approval. DCGI has approved for production with Sputnik-Vina examination, test and analysis.

Notably, the serum is already producing the covid vaccine Covishield. But now the company will also produce the Russian vaccine Sputnik. The Serum Institute applied to DCGI for tests, analysis and examination.

At present in India, Dr. Reddy's Laboratory is also producing Sputnik-V. The Russian vaccine was first used on May 14. So far Sputnik is registered in more than 50 countries. According to a study, the effectiveness of this vaccine (both doses) is 97.6 percent.

The Serum Institute demands that, like foreign vaccine companies, they be protected by the government. Apart from that, other domestic vaccine companies are also demanding that if foreign companies get this facility, they should also get government protection.

In fact, US vaccine makers Pfizer and Moderna have demanded protection from the government. So that if there is any problem after taking the vaccine, no one can take legal action against the company. Now, in addition to serum, Bharat Biotech is also making such a demand.